LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

LLY

1,009.85

-2.98%↓

JNJ

242.53

-0.92%↓

ABBV

221.21

-3.94%↓

NVS

164.89

-1.75%↓

MRK

119.17

-3.26%↓

Начало・Списък с акции・Fate Therapeutics Inc

Fate Therapeutics Inc

Отворен

СекторЗдравеопазване

1.45 -9.94

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.3900000000000001

Максимум

1.6099999999999999

Ключови измерители
By Trading Economics
Приходи	1.8M -32M
Продажби	-166K 1.7M
Марж на печалбата	-1,852.384
Служители	181
EBITDA	7.9M -29M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+193.21% upside

Дивиденти
By Dow Jones
Следващи печалби	3.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	48M 174M
Предишно отваряне	11.39
Предишно затваряне	1.45

Настроения в новините

By Acuity

50%

167 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

0.9101 / 1.14 Подкрепа & съпротива

Fate Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2026 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25.02.2026 г., 23:15 ч. UTC

Печалби

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25.02.2026 г., 23:54 ч. UTC

Пазарно говорене

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25.02.2026 г., 23:47 ч. UTC

Печалби

Ferrovial 4Q Net EUR197M >FER.MC

25.02.2026 г., 23:45 ч. UTC

Печалби

Ferrovial 4Q Rev EUR2.72B >FER.MC

25.02.2026 г., 23:42 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Company's Business Operations Remain Normal >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25.02.2026 г., 23:25 ч. UTC

Печалби

Trip.com FY EPS CNY47.67 >TCOM

25.02.2026 г., 23:06 ч. UTC

Печалби

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25.02.2026 г., 23:01 ч. UTC

Печалби

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

25.02.2026 г., 23:00 ч. UTC

Пазарно говорене

Печалби

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25.02.2026 г., 22:56 ч. UTC

Пазарно говорене

Печалби

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25.02.2026 г., 22:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25.02.2026 г., 22:40 ч. UTC

Пазарно говорене

Печалби

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25.02.2026 г., 22:40 ч. UTC

Печалби

Karoon Energy Says Search for New CFO Well Advanced

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says CFO Ray Church to Leave Company

25.02.2026 г., 22:39 ч. UTC

Печалби

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25.02.2026 г., 22:38 ч. UTC

Печалби

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Сравнение с други в отрасъла

Ценова промяна

Fate Therapeutics Inc Прогноза

Ценова цел

By TipRanks

193.21% нагоре

12-месечна прогноза

Среден 4.75 USD 193.21%

Висок 7 USD

Нисък 2.5 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Fate Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Fate Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.9101 / 1.14Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Настроение

By Acuity

167 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.